ANDA 40136, held by Am Regent. Hydralazine Hydrochloride.
As of Nov 16, 2026, ANDA 40136 (Hydralazine Hydrochloride), held by Am Regent, was first approved by FDA on Jun 30, 1997, with 2 approved supplements and 0 published complete response letters.
Severe essential hypertension when the drug cannot be given orally or when there is an urgent need to lower blood pressure.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 30, 1997 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Hydralazine Hydrochloride20MG/ML · injectable;injection | Hydralazine Hydrochloride | Rx |
| Oct 28, 2024 | Supplement 13Labeling · Standard review | Approved | None posted |
| Apr 26, 2013 | Supplement 5Labeling · Standard review | Approved | |
| Jun 30, 1997 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters